Fig. 6. Representative microfluidic-based cardiovascular models for drug discovery.
a Evaluation of the smoothing effect of hydralazine hydrochloride in hypertension. b Investigation of the antiplatelet capacities of aspirin and eptifibatide. c Evaluation of the antiplatelet effects of abciximab and cangrelor. d Study of the anticoagulant effects of dabigatran and rivaroxaban with aspirin and AR-C66096 as regulatory factors. Microfluidic-based heart models for drug discovery (e, f). e High-throughput evaluation of the inotropic effects of isoproterenol and digoxin. f Investigation of the pharmacological properties of verapamil and metoprolol. a Reproduced with permission43. Copyright 2014, American Chemical Society. b Reproduced with permission90. Copyright 2014, PLOS. c Reproduced with permission91. Copyright 2014, PLOS. d Reproduced with permission92. Copyright 2016, American Chemical Society. e Reproduced with permission95. Copyright 2011, The Royal Society of Chemistry. f Reproduced with permission47. Copyright 2015, Springer Nature.